医学
精密医学
重症监护医学
不利影响
梅德林
生物标志物
个性化医疗
风险评估
肿瘤科
内科学
生物信息学
临床试验
荟萃分析
系统回顾
作者
Eva Hilger,Kaitlyn R Chan,Alphonsus Yip,Xingyue Maria Wang,Conor Broderick,Bernd W. M. Arents,Karin van Bart,Kilian Eyerich,Joseph M. D. Rastrick,Stephan Weidinger,Carsten Flohr
摘要
INTRODUCTION AND OBJECTIVES: Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease characterized by intense itch that affects approximately 20% of children and up to 10% of adults. Our systematic review aims to identify biomarkers with clinical significance for predicting response to systemic therapies and treatment-related adverse events (AEs) for AD patients. MATERIALS AND METHODS: A systematic search was conducted across the electronic databases Embase and MEDLINE from database inception to September 2024. All records were independently screened at both the title/abstract and full-text stages. Included articles were randomized controlled trials, cohort studies or case-control studies that reported relevant data for investigating associations between biomarkers and disease progression and/or change in disease activity over time. All discrepancies at any stage were resolved through adjudication by a senior reviewer. RESULTS: We identified 28 papers evaluating biomarkers for treatment response and 11 for AEs. Across treatment response studies, biomarkers investigated included IgE, eosinophils, LDH, TARC, cytokines, genetic variants and the skin microbiome. Most studies investigated the association between biomarkers and dupilumab, while studies reporting associations between biomarkers and AEs were limited to dupilumab-related conjunctivitis and ocular surface disease (DAOSD). The primary findings on treatment response were inconsistent, demonstrating that while elevated LDH was associated with poorer response to dupilumab, neither IgE nor eosinophil count showed consistent predictive value. Regarding the association between biomarkers and AEs, IgE was identified as the most promising predictor of DAOSD. CONCLUSIONS: Predicting therapeutic responses and identifying patients at risk of developing AEs will be increasingly important with an expanding range of treatment options for AD. Finding robust predictive biomarkers for AD, however, is complicated by its clinical heterogeneity and multifactorial aetiology. Collaborative projects, such as BIOMAP, hold great potential to advance precision medicine and enhance individualized care.
科研通智能强力驱动
Strongly Powered by AbleSci AI